Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form S-3) and related Prospectus of Prelude Therapeutics Incorporated for the registration of 6,250,000 shares of its common stock and to the incorporation by reference therein of our report dated March 10, 2025, with respect to the financial statements of Prelude Therapeutics Incorporated  included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

December 10, 2025